Galectin Therapeutics Inc. (GALT) Stock Forecast
GALT analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $11.00 average of analyst targets
- Upside to target
- +203.9% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.05
- 52-week range
- $2.08 – $6.51
GALT analyst ratings
1 analystsNumber of analysts at each rating.
GALT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GALT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.05 | −$0.05 | −$0.13 | +61.5% | 1 |
| Current fiscal year (2026) | −$0.30 | −$0.30 | −$0.30 | −$0.48 | +37.5% | 1 |
| Next fiscal year (2027) | −$0.23 | −$0.23 | −$0.23 | −$0.30 | +23.3% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GALT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
GALT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GALT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.10 | −$0.10 | −$0.10 | −$0.05 | −50.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.37 | −$0.37 | −$0.37 | −$0.37 | −$0.30 | −18.9% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.33 | −$0.33 | −$0.33 | −$0.33 | −$0.23 | −30.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GALT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GALT beat in 4 of 12.
What analysts expect from GALT
1 analysts cover Galectin Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.00, 203.9% above the latest close of $3.62. Analysts expect earnings of −$0.30 per share for 2026, +37.5% from a year earlier. For 2027 the average estimate is −$0.23 per share. Galectin Therapeutics beat the EPS estimate in 4 of the last 12 quarters.
Related: GALT income statement, GALT key metrics, GALT chart. See the GALT stock overview for the latest quote and news.
GALT forecast FAQ
What is Galectin Therapeutics's price target?
The average analyst price target for Galectin Therapeutics is $11.00, 203.9% above the latest close of $3.62.
Is Galectin Therapeutics a buy, hold or sell?
Of 1 analysts covering Galectin Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Galectin Therapeutics's EPS forecast?
Analysts forecast −$0.30 per share for 2026 (range −$0.30 to −$0.30); for 2027 the estimate is −$0.23.
When does Galectin Therapeutics report earnings?
Galectin Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.05.
Does Galectin Therapeutics usually beat earnings estimates?
Galectin Therapeutics reported EPS at or above the analyst estimate in 4 of the last 12 quarters.